Drug Detail

Information about BKM120

Generic Name
IND	BKM120
Brand Name (US)
Manufacturer	Novartis
Drug Type	Kinase inhibitor
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block KIT Signal Path
Drug Category	PI3K inhibitor

BKM120 is a selective PI3K inhibitor made by Novartis. It is in phase I trials at the Sarah Cannon Research Institute.
Unlike BEZ235 and BGT226 (also from Novartis), BKM120 does not inhibit the mTOR pathway.
A phase I trial combining BKM120 and 400 mg of imatinib is listed as not yet recruiting in clinicaltrials.gov (Nov. 22nd, 2011).